PATENT CLAIM ANALYSIS

Application Number: 16262442
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["424", "093200"]

Abstract:
Malignant tumors that are resistant to conventional therapies represent significant therapeutic challenges. An embodiment of the present invention provides an oncolytic virus capable of killing target cells, such as tumor cells. In various embodiments presented herein, the oncolytic viruses described herein are suitable for treatment of several types of cancer, including glioblastoma.

Claim (Index 6):
The method of  claim 1 , wherein the expression control sequence comprises a nestin promoter or a biologically active portion thereof.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 99.0
- Lexical Diversity: 1.26087
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14442632', '12697891', '14343108', '16126370', '15489514']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7172643440921881
- 35 USC 102 Novelty (BERT): 0.594942895977871
- Combined Prediction Score: 0.7050321992807564
- Mean Citation Score: 378.985192
- Max Citation Score: 537.4053
- Similarity Product: 438.2253649176657

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test